D. Western Therapeutics Institute, Inc.
4576.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.02B
Close$
Share Statistics
| Market cap | $4.02 Billion |
|---|---|
| Enterprise Value | $3.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-13.19 |
| Beta | -0.01 |
| Outstanding Shares | 57,472,025 |
Return
| Return on Equity | -45.30% |
|---|---|
| Return on Assets | -31.14% |
| Return on Invested Capital | -33.71% |
Valuation & Multiples
| P/E Ratio | -5.88 |
|---|---|
| PEG | 72.19 |
| Price to Sales | 17.5 |
| Price to Book Ratio | 2.92 |
| Enterprise Value to Revenue | 12.22 |
| Enterprise Value to EBIT | -4.82 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.41 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About D. Western Therapeutics Institute, Inc.
19 employees
CEO: Yuichi Hidaka D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutio...